Efficacy of Eculizumab in Myasthenia Gravis Patients with Poor Response to Efgartigimod

A prospective cohort study of 103 patients with generalized myasthenia gravis (gMG) who received efgartigimod, focusing on 18 patients with an inadequate early response who were subsequently treated with eculizumab. Clinical outcomes were assessed using MG-ADL and QMG scores, with data collected by Xueting An and last updated in May 2026. The dataset likely contains patient-level clinical scores and treatment response metrics.

Use Cases

• Analyzing treatment response trajectories based on MG-ADL and QMG score changes mentioned in the description
• Modeling patient outcomes for sequential therapies based on the described cohort of poor early responders
• Investigating the safety profile of complement inhibition therapies based on adverse event reporting
• Studying the correlation between glucocorticoid dose reduction and clinical improvement metrics

Strengths

• Includes longitudinal follow-up data for 12 patients over 16 weeks
• Reports specific clinical outcome scores (MG-ADL and QMG) with statistical significance (P < 0.001)
• Documents adverse event reporting for safety evaluation

Limitations

• Row count is unknown, which may limit suitability assessment
• Column-level documentation is absent; field semantics must be inferred after download
• Data may reflect selection bias inherent to a single-center prospective cohort study

Provenance

Source

Xueting An

Collection Method

Prospective cohort study

Freshness

Last updated 2026-05-25 06:03:29; freshness should be verified